Clinical Trial Update: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) [Phase 3]

View source ↗

Summary

A Phase 3 efficacy and safety trial evaluating 12 weeks of nebulized SUN-101 in COPD has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SUN-101 (glycopyrrolate)

Snippet

Sponsor: Sunovion Respiratory Development Inc. | Conditions: COPD, Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-03-13